# A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

> **NCT03290443** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 31 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Enasidenib

## Key facts

- **NCT ID:** NCT03290443
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-21
- **Primary completion:** 2018-10-26
- **Final completion:** 2018-10-26
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03290443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03290443, "A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03290443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*